# Study 102: Multiple Ascending Dose Study of ALLN-346 (Engineered Urate Oxidase)

> **NCT04829435** · PHASE1 · COMPLETED · sponsor: **Allena Pharmaceuticals** · enrollment: 18 (actual)

## Conditions studied

- Hyperuricemia
- Gout

## Interventions

- **DRUG:** ALLN-346
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04829435
- **Lead sponsor:** Allena Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-21
- **Primary completion:** 2021-06-01
- **Final completion:** 2021-06-01
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2021-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04829435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04829435, "Study 102: Multiple Ascending Dose Study of ALLN-346 (Engineered Urate Oxidase)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04829435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*